Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regenxbio Inc (NQ: RGNX )

15.87 +0.52 (+3.36%)
Streaming Delayed Price Updated: 11:17 AM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Regenxbio Inc

< Previous 1 2 3 4 5 Next >
Where Regenxbio Stands With Analysts
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
The threat is still emerging, but it could be significant. 
Via The Motley Fool
This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO
REGENXBIO's promising gene therapy advancements! RBC Capital Markets upgraded REGENXBIO (RGNX), citing impressive RGX-202 trial results in Duchenne patients. 
Via Benzinga
Beyond The Numbers: 4 Analysts Discuss Regenxbio Stock
Via Benzinga
REGENXBIO's Muscle Wasting Disorder Drug Shows Strength, Improved Motor Function, Stock Soars
Latest updates on safety and efficacy in the Phase 1/2 AFFINITY DUCHENNE trial for Duchenne muscular dystrophy. Positive results, no serious adverse events. Expect pivotal dose determination by... 
Via Benzinga
Regenxbio: Q4 Earnings Insights
Via Benzinga
Earnings Scheduled For February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
A Preview Of Regenxbio's Earnings
Via Benzinga
Earnings Preview For Regenxbio
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results. 
Via Benzinga
What 4 Analyst Ratings Have To Say About Regenxbio
Via Benzinga
The Latest Analyst Ratings for Regenxbio
Via Benzinga
Earnings Preview: Regenxbio
Via Benzinga
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst
Insights from Wedbush analysts about the clinical effectiveness of REGENXBIO's RGX-202, market potential, and challenges posed by competitors like Sarepta Therapeutics and Pfizer. 
Via Benzinga
The One-Minute Market Report - Sunday, Feb. 11
In this brief market report, we will take a look at the various asset classes, sectors, equity categories, exchange-traded funds, and stocks that moved the market higher, as well as the market segments... 
Via Talk Markets
Jim Cramer Says Investors Should Look Beyond Apple, Meta And Other Magnificent 7 Stocks: 'You Might Be Missing Out On Some Huge Gains'
Jim Cramer, the host of CNBC's "Mad Money," has suggested that investors should look beyond the Magnificent Seven tech stocks for potential high-yield investments. 
Via Benzinga
Why Is Blindness Focused-Adverum Biotechnologies Stock Trading Lower Today?
Adverum Biotechnologies' Ixo-vec gene therapy for wet AMD. Preliminary LUNA Phase 2 trial data show safety, efficacy, and significant treatment burden reduction. 
Via Benzinga
Why Is Gene Therapy-Focused REGENXBIO Stock Trading Higher Today?
REGENXBIO's progress in Duchenne muscular dystrophy and MPS II treatment trials. Interim results for RGX-202 in Phase 1/2 trial and significant milestones achieved in Phase 1/2/3 trial with RGX-121. 
Via Benzinga
Chipotle Posts Upbeat Earnings, Joins Cirrus Logic, Emerson Electric, Carlyle Group And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Container Store Group Shares Are Trading Lower By Around 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of The Container Store Group, Inc. (NYSE: TCS) shares fell sharply during Wednesday’s session following weak quarterly results. 
Via Benzinga
Ocular Gene Therapy: Regenxbio Data Shows Consistent Preservation Of Visual Acuity, Retinal Thickness
Regenxbio's latest trial data on ABBV-RGX-314 reveal 80% reduction in injection rate, 50% injection-free, and no intraocular inflammation. 
Via Benzinga
Progress Software Posts Strong Q4 Results, Joins Impinj, REGENXBIO And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow Jones futures falling more than 100 points on Wednesday. Shares of Progress Software Corporation (NASDAQ: PRGS) rose in pre-market trading as... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on... 
Via Benzinga
Boeing, Pacific Biosciences of California And Other Big Stocks Moving Lower On Monday
U.S. stocks traded mixed, with the Dow Jones index falling around 80 points on Monday. Shares of The Boeing Company (NYSE: BA) fell during Friday’s session after an exit door blew out of a 737 aircraft... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 369 companies hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  Monday's session saw 175 companies set new 52-week lows. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.